

# Brigitte Wildemann

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4975931/brigitte-wildemann-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92  
papers

6,064  
citations

38  
h-index

77  
g-index

98  
ext. papers

7,586  
ext. citations

7.6  
avg, IF

5.42  
L-index

#	Paper	IF	Citations
92	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , <b>2016</b> , 13, 280	10.1	468
91	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , <b>2012</b> , 9, 14	10.1	449
90	Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>Journal of Neurology</i> , <b>2014</b> , 261, 1-16	5.5	373
89	AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. <i>Nature Reviews Neurology</i> , <b>2010</b> , 6, 383-92	15	326
88	Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. <i>European Journal of Immunology</i> , <b>2005</b> , 35, 3343-52	6.1	319
87	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. <i>Journal of Neuroinflammation</i> , <b>2016</b> , 13, 279	10.1	255
86	Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. <i>Nature Clinical Practice Neurology</i> , <b>2008</b> , 4, 202-14		240
85	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , <b>2016</b> , 79, 206-16	9.4	219
84	Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. <i>Journal of Immunology</i> , <b>2007</b> , 179, 1322-30	5.3	190
83	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. <i>Journal of Neuroinflammation</i> , <b>2016</b> , 13, 282	10.1	158
82	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1005-15	5.5	157
81	Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. <i>Brain Pathology</i> , <b>2013</b> , 23, 661-83	6	149
80	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. <i>Journal of Neuroinflammation</i> , <b>2016</b> , 13, 281	10.1	148
79	The history of neuromyelitis optica. <i>Journal of Neuroinflammation</i> , <b>2013</b> , 10, 8	10.1	134
78	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. <i>Journal of the Neurological Sciences</i> , <b>2010</b> , 298, 158-62	3.2	134
77	Diagnostic criteria for Susac syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1287-9	5.3	130
76	Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. <i>Journal of Immunology</i> , <b>2003</b> , 171, 432-7	5.3	116

75	Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2018</b> , 5, e504	9.1	111
74	Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2009</b> , 216, 113-7	3.5	89
73	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 639-647	5.5	88
72	Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , <b>2020</b> , 6, 85	51.1	77
71	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , <b>2016</b> , 2, e1501678	14.3	75
70	Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in pattern II multiple sclerosis and brain biopsy findings in a MOG-IgG-positive case. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1541-1549	5	75
69	Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. <i>Archives of Neurology</i> , <b>2008</b> , 65, 1434-9		75
68	Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. <i>PLoS ONE</i> , <b>2011</b> , 6, e17988	3.7	68
67	Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 1189-97	5	52
66	GABAB receptor antibodies in paraneoplastic cerebellar ataxia. <i>Journal of Neuroimmunology</i> , <b>2013</b> , 256, 94-6	3.5	49
65	T-cell homeostasis in pediatric multiple sclerosis: old cells in young patients. <i>Neurology</i> , <b>2013</b> , 81, 784-926.5		49
64	B cells undergo unique compartmentalized redistribution in multiple sclerosis. <i>Journal of Autoimmunity</i> , <b>2011</b> , 37, 289-99	15.5	49
63	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 44, 102251	4	46
62	CD8 T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. <i>Nature Communications</i> , <b>2019</b> , 10, 5779	17.4	46
61	A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. <i>Journal of Neuroinflammation</i> , <b>2010</b> , 7, 21	10.1	45
60	Immunopathogenesis of neuromyelitis optica. <i>Advances in Immunology</i> , <b>2014</b> , 121, 213-42	5.6	43
59	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. <i>Neurology</i> , <b>2015</b> , 85, 610-8	6.5	40
58	Treatment choices and neuropsychological symptoms of a large cohort of early MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2018</b> , 5, e446	9.1	40

57	Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis. <i>Journal of Immunology</i> , <b>2013</b> , 190, 4965-70	5.3	40
56	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2016</b> , 3, e204	9.1	39
55	Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography. <i>Annals of Neurology</i> , <b>2017</b> , 82, 676-685	9.4	38
54	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. <i>BMJ Open</i> , <b>2016</b> , 6, e010956	3	38
53	Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia. <i>Journal of Neuroinflammation</i> , <b>2014</b> , 11, 206	10.1	36
52	Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. <i>Journal of Neuroinflammation</i> , <b>2013</b> , 10, 7	10.1	32
51	The interleukin-7 receptor $\alpha$ chain contributes to altered homeostasis of regulatory T cells in multiple sclerosis. <i>European Journal of Immunology</i> , <b>2011</b> , 41, 845-53	6.1	32
50	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. <i>Journal of Neuroinflammation</i> , <b>2020</b> , 17, 261	10.1	32
49	Herpes simplex virus encephalitis: chronic progressive cerebral MRI changes despite good clinical recovery and low viral load - an experimental mouse study. <i>European Journal of Neurology</i> , <b>1999</b> , 6, 531-8	6	31
48	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 681-686	5.5	30
47	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , <b>2020</b> , 56, 102807	8.8	30
46	Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e363	9.1	29
45	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2019</b> , 76, 841-849	17.2	28
44	Anti-Ca/anti-ARHGAP26 antibodies associated with cerebellar atrophy and cognitive decline. <i>Journal of Neuroimmunology</i> , <b>2014</b> , 267, 102-4	3.5	27
43	A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. <i>Immunology and Cell Biology</i> , <b>2015</b> , 93, 396-405	5	26
42	Failure of alemtuzumab therapy to control MOG encephalomyelitis. <i>Neurology</i> , <b>2017</b> , 89, 207-209	6.5	24
41	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , <b>2020</b> , 94, e407-e418	6.5	23
40	Prednisolone and azathioprine are effective in DPPX antibody-positive autoimmune encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2015</b> , 2, e86	9.1	21

39	Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. <i>European Journal of Neurology</i> , <b>2021</b> ,	6	21
38	Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy. <i>Journal of Neurochemistry</i> , <b>2020</b> , 153, 650-661	6	21
37	Molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis. <i>Annals of Neurology</i> , <b>2000</b> , 47, 211-217	9.4	20
36	Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 381, 240-244	3.2	20
35	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , <b>2019</b> , 266, 386-397	5.5	19
34	Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1521-32	5	18
33	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. <i>Journal of Neuroinflammation</i> , <b>2020</b> , 17, 262	10.1	18
32	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. <i>Journal of Neuroinflammation</i> , <b>2016</b> , 13, 278	10.1	17
31	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	17
30	Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. <i>Journal of Neurology</i> , <b>2017</b> , 264, 341-349	5.5	15
29	Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2016</b> , 294, 18-26	3.5	15
28	Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. <i>Journal of Neurology</i> , <b>2019</b> , 266, 165-173	5.5	15
27	Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature. <i>Journal of Neurology</i> , <b>2018</b> , 265, 239-252	5.5	15
26	Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 114-118	5	14
25	Sodium MRI in Multiple Sclerosis is Compatible with Intracellular Sodium Accumulation and Inflammation-Induced Hyper-Cellularity of Acute Brain Lesions. <i>Scientific Reports</i> , <b>2016</b> , 6, 31269	4.9	14
24	Rapid distinction of acute demyelinating disorders and central nervous system lymphoma by molecular analysis of cerebrospinal fluid cells. <i>Journal of Neurology</i> , <b>2001</b> , 248, 127-30	5.5	13
23	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	13
22	From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum. <i>Journal of Neuroimmunology</i> , <b>2017</b> , 309, 77-81	3.5	12

21	Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2018</b> , 5, e480	9.1	12
20	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. <i>Pain</i> , <b>2020</b> , 161, 787-796	8	12
19	Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1204	8.4	11
18	The expanding range of autoimmune disorders of the nervous system. <i>Lancet Neurology</i> , <b>2013</b> , 12, 22-4	24.1	11
17	Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2021</b> , 92, 1007-1013	5.5	11
16	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , <b>2015</b> , 39, 601-8	2.6	9
15	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	7
14	Neurology--the next 10 years. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 658-64	15	6
13	Pain, depression, and quality of life in adults with MOG-antibody-associated disease. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 1645-1658	6	6
12	Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg. <i>Journal of Neuroimmunology</i> , <b>2015</b> , 278, 60-8	3.5	5
11	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients.. <i>Journal of Neuroinflammation</i> , <b>2022</b> , 19, 19	10.1	5
10	Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. <i>Brain</i> , <b>2021</b> , 144, 3126-3141	11.2	5
9	Is $\beta$ associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	4
8	Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2016</b> , 301, 53-60	3.5	3
7	Genetic determinants of the humoral immune response in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	3
6	Transient MOG antibody seroconversion associated with immunomodulating therapy. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 37, 101420	4	3
5	MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis. <i>Acta Neuropathologica</i> , <b>2021</b> , 141, 127-131	14.3	3
4	Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155322	3.7	2

3	COVID-19-related severe MS exacerbation with life-threatening Takotsubo cardiomyopathy in a previously stable patient and interference of MS therapy with long-term immunity against SARS-CoV-2. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	2
2	Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. <i>Journal of Neurochemistry</i> , <b>2021</b> , 158, 522-538	6	1
1	Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis. <i>Journal of Neurology</i> ,	5.5	0